written by reader Another Hot Australian Biotech: Is Biotron Right for Your Portfolio?

by DrKSSMDPhD | April 5, 2014 12:41 pm

This is premium content. To view this article (and to have full access to the rest of our articles), sign up. Already a member? Log in.

Source URL: https://www.stockgumshoe.com/2014/04/microblog-another-hot-australian-biotech-is-biotron-right-for-your-portfolio/


1,174 responses to “written by reader Another Hot Australian Biotech: Is Biotron Right for Your Portfolio?”

  1. pana says:

    Happy Easter to all.
    Maybe this is the right time to review an other Aussie Biotech;
    Clinuvel Pharma ticker CUV .
    Could get very interesting in the next months

  2. pana says:

    Well their lead drug SCENESSE is up for EMEA review in june.
    My field is Electronics, so I have a hard time going into specific scientific details.
    But as far as I can Judge this is worth taking a closer look at.

  3. quantum007 says:

    Luv a good curry mate… but i do miss the fish n chips… I travel to London every now and then. Don”t miss the crowds and cues, but do miss the magical energy that”s in the air and unique to London. Chizzy Lad aye, Good on Ya

  4. Frenchy says:

    I thought Dr KSS knew who this sleazeball was regurgitating false info on SA. Perhaps it is time to block him/her?

  5. Alan Harris says:

    So you’re gonna spend big dosh suing Mrs Jones?? The whole idea of keeping a secret on the internet is laughable. As you say…..Gumshoe was founded on busting supposedly ‘secret ‘ info. So long as its author is intelligent enough to know that their comments may go viral…then that adds to the checks and balances over the quality of what they write. And if it helps to spread the word about what they’re missing by not spending a whole $49 on joining GS, then hopefully we’ll get even more educated comment here….win win.

    Theres no hiding place on the net. Publish and be ….creditted.

  6. vivianlewis says:

    I feel like Ariadne trying to sort out the thread to save her lover–who then dumped her.
    A few comments on this wild and woolly thread:
    Philip Frost is a mad AND bad stock manipulator rather than a scientist and Opko is his vehicle. He more or less owns it because he buys to support the price. It has just switched to becoming Opko Bio Research, with the same ticker symbol and since it is listed in Israel as well as the USA people are trying to figure out what its target company may be as it raised lots of funding recently.
    I ran into a US based IR with a PhD in biochemistry who covers Benitec and Biotime and Antisense, among others. Josh Drumm. His NYC phone is disconnected (why? is biz that bad?) but you can reach him by email at jdrumm@tiberend.com
    And in case nobody noticed the reason that Questor rose was that insiders knew there was going to be a complex tax-evading merger into Mallinckrodt, MNK, which we own. It was spun off by Covidien about 16 months ago. Both are Irish. This gives QCOR lower taxes.
    to Linnea Due, good to see you again. You are going to have to bite the bullet and go to a broker which offers global trading. They all charge you for it, but my fave is E-trade which only charges if you go to the foreign market; not for the thinly traded American Depositary Receipt or ADR. These exist for almost all the foreign stocks mentioned in this tangle (AKA thread). Happy Easter

  7. jlw3262 says:

    Great explanation Travis and Alan. Too bad those SA lurkers don’t have the courtesy to wait till we back up the truck. Alan, look forward to seeing your plumbers crack in OZ when we are all rich. JZ thank you for all you do for us, and please sign me up for your options seminar. I really look forward to it and I know many of our brethren and sistern do too. BTW, Alan are we all moving to the new Dr KSS thread now?

  8. Alan Harris says:

    Courtesy is in short supply among the ego centric. Yes, I guess we are all moving….but I will start the usual Regado Eyes and Ears discussion/chat room, so that all consequential research (and ephemera ) can be posted there to keep the new thread less cluttered. (Im a natural optimist)

  9. KennyG says:

    Those of you that have holdings or a interest in Cubist Pharma (CBST) may find this interesting. A recall of one of their drugs, Cubicin:
    http://www.dddmag.com/news/2014/04/breaking-news-cubist-recalls-cubicin-lot?et_cid=3891718&et_rid=674872822&type=cta

  10. Subramania Kaushik says:

    All QRXPY longs who are locked in before the ADCOMM review, here is an interesting read!

    http://seekingalpha.com/article/2147293-hidden-australian-life-sciences-growth-stocks-revealed-scott-power

  11. DrKSSMDPhD says:

    To James Fernow: about THAT article and Provectus and PV-10: HAHAHAHAHAHAHAHAHAHAHA!!!! Not laughing at you, but HAHAHAHAHAHAHAHA! I know that author, and HAHAHAHAHAHAHAHAHAHAHAHAHAHAHA!!! I have dealt with that author and HAHAHAHAHAHAHAHAHAHAAHA! “Surgical Oncology”…..best oxymoron of all time…HAHAHAHAHAHAHAHAHAHAHAHAHAHAHA! Rose Bunghole for cancer….HAHAHAHAHAHAHA! “Nobel Prize” for this work as hinted at….secret insider knowledge imparted by someone who cannot be named, someone speaking in a fierce whisper…….”.pssssst, hey mack, wanna buy a stock tip??? I have it on good authority Moffitt applied for a Nobel Prize for Rose Bengal”…….HAHAHAHAHAHAHAHAHAHAHAAHAHAHAHA! You can send in an application for a Nobel Prize, yeah, if you log onto the Close Cover Before Striking Institute website, fill in a form, send a money order along with 10 Cheerios boxtops and complete an application: “My work deserves a Nobel Prize because: (dropdown menu, check all that apply): (1) I always floss, (2) I always open doors for ladies, (3) doggoneit, people like me!, (4) I have never removed any “do not remove this tag” tags from ANY mattresses.”

    You can fool all of the people some of the time, but PVCT investors are the subset of those you can fool all of the time. PVCT, ummhmmm, in that biotech mecca Knox veee-ille Tennessee. When your work is so crummy that you have to retrench by floating a couple of posters at AACR with boondoggling putative “immune” mechanisms for how your non-agent (an insecticide) works……seriously, Rose Bengal always behaves JUST THE WAY Provectus wants it to behave…..immune-potentiating here, immune-suppressive there, Cures cancer, cures psoriasis. They can’t decide if it causes necrosis, apoptosis or an immune response….they have put out posters arguing all three, and when conflicting data emerge, they bury the old posters. They’ll feint and hedge and dodge….ANYTHING to keep from starting phase III. People do not seem to understand that getting orphan drug designation does NOT mean the FDA thinks your agent has value, but only that you are chasing something rare, an uncommon condition. This stock is controlled by a tiny cloister of boogie-woogie bubba boys who are all utterly soused on their own Rose Bengal-colored Kool-Aid. When I feel down or lonely and need to laugh, I always log onto the PVCT website and it never fails to bring on the hilarity. To an oncologist, to a bioscience PhD, to a critical thinker, this work is so far off base as to just be dismissible without much comment. I urge you not to be suckered in by this. I truly am not jumping on you, or on anybody, but this is among the most easily debunked plays in biotech.

  12. 1paglee says:

    Finally, here’s some technical good news from the Nasdaq Biotechnology index — The first link below shows a candlestick chart that yesterday gave two favorable signals. There was a clear candlestick “gap up”, and a moving-average “golden cross” after the “death cross” that occurred around the first of March, with a continuing decline of the average since then –until yesterday

    http://stockcharts.com/h-sc/ui?s=$NBI&listNum=

    The next link below shows a P&F chart with a “low-pole” buy signal of rising “x boxes” followed by a bullish rise at 2460, one “box” above the previous column of rising x boxes. However, note the descending trend line colored red. This indicates there may be strong resistance for a rise above 2480. But if that red line is penetrated, this could signal more good news to come.

    http://stockcharts.com/def/servlet/SC.pnf?c=$NBI,P&listNum=

    In checking my Biotech account at Fidelity around noon today, I was delighted to note ten strong rises since yesterday that were above 10%, and one miserable decline of 15.6% for MDFZF (Medifocus. Anybody know a reason for this deadly drop, particularly during a strong market-rise?

    There were lots of other gainers, but my best rises (in alphabetical order) were for BDSI 11.5%; EXC:DE (Epigenomics) 13.2%; ECYT 11.1%; GNFT:FR (Genfit) 10.1%; ICPT 16.7%; IDRA 18.3%; MRNA 21.3%; OMER 10.1%; OPHT 10.2%; QURE 10.1%; RUNC 14.2%. Generally such strong risers make good buy candidates, at least during the next correction.

    I noticed that Benitec had dropped slightly, offering what seemed a buying opportunity, so I bought some more BNIKF at E Trade (as suggested in some previous comments, thank you) instead of from Fidelity, thereby (for once) I escaped that onerous $50 Fidelity foreign-commission overcharge

    Dr. KSS — has there been any recent news on Benitec?

  13. 1paglee says:

    Regarding No. 452, as an update to the minimal technical analysis I posted yesterday, please note that the links still work OK and if you use them again today, they will show the latest data on the Nasdaq Biotechnology Index. The upper one will show a new red candlestick indicating a small drop in the index, but the lower P&F chart is more interesting. If you click on the link, you will see that the big rising column of black “x boxes” has reversed into a falling column of red “o boxes”, and currently has recovered slightly from a bottom at 2400 into a slightly improved value of around 2400.

    It will not represent a bearish pattern until it falls to around 2330, but hopefully it may reverse upward again, but such a possible upward reversal will not be confirmed unless and until it reaches 2430 (as conditions now stand). However, to reconfirm a bullish pattern the index must reach or exceed 2470, but first it must penetrate an extension of the red downtrend line that (in effect) should now be extended into the box at 2460. So 2460 may become a new hazardous barrier to any further upward recovery. It is unfortunate that the prior rising column did not get to 2470 and at least bump into the red descending trend line, so having reached only 2460, barely one x box above the prior rising column of x boxes. In P&F analysis, this pattern can represent a “bull trap” when the column reverses immediately after only one higher x box.

    But today’s falling action may be in sympathy with today’s falling Nasdaq market which coulee be normal after such a rapid recent rise. Some natural consolidation may be in order now.

  14. 1paglee says:

    Just in case I was overly exuberant yesterday about the market in Biotech stocks, I am pasting below a P&F chart for the Nasdaq:

    http://stockcharts.com/def/servlet/SC.pnf?c=%24COMPQ,P

    You may notice that the P&F connoisseurs who created this Nasdaq chart have put a bearish red-colored PO (price objective) of 3500 based on the pattern configuration of the chart. This is probably based on the latest down-column of “O’s” showing a dangling “O box” at 3950, and being one box lower than the red “2” (at 4000) shown in the prior down column of O’s. P&F predictions can be wrong, but I bring this up because if Nasdaq were to drop about 15% according to this very bearish PO, the Nasdaq Biotech index will likely fall also.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.